Hayat Pharmaceutical Industries Company PSC

Hayat Pharmaceutical Industries Company PSC maintains a strong liquidity position, with a current ratio of 4.79, indicating that it has more than four times the current assets to cover its current liabilities. The company also holds significant cash and equivalents of JOD 6,075,120, which provides a buffer against short-term obligations. The liquidity risk is assessed as low, supported by the absence of immediate filing-based liquidity flags.

In terms of profitability, the company's return on equity (ROE) is 1.08%, and its return on assets (ROA) is 0.9%, both of which are below the typical thresholds for high-performing pharmaceutical firms. These metrics suggest that the company is not generating strong returns relative to its equity and asset base. The operating margin, calculated as operating income of JOD 179,790 on revenue of JOD 2,520,460, is 7.13%, which is in line with the industry median for pharmaceutical companies.

Hayat Pharmaceutical Industries Company PSC operates in a single business segment, with no disclosed geographic diversification. The company's revenue is entirely derived from its pharmaceutical operations, and there is no indication of revenue concentration across multiple regions or product lines. This lack of diversification may expose the company to higher operational and market risks if demand for its products fluctuates.

The company's growth trajectory appears to be modest, with no significant revenue growth reported in the latest financial period. The operating cash flow is negative at JOD -1,205,370, which may indicate challenges in converting sales into cash. However, the free cash flow is positive at JOD 521,810, suggesting that the company is able to generate cash after capital expenditures. The capital expenditure of JOD -77,170 indicates a relatively low level of investment in new assets, which may limit future growth potential.

The risk assessment for Hayat Pharmaceutical Industries Company PSC indicates a low probability of dilution, with no immediate filing-based dilution flags detected. The company's debt-to-equity ratio is 0.07, which is low and suggests a conservative capital structure. However, the negative operating cash flow could be a concern if it persists, as it may necessitate additional financing, which could lead to increased leverage or dilution.

Recent events and filings do not indicate any material changes in the company's operations or financial position. The company has not issued any new shares or taken on significant debt in the latest reporting period. There are no notable regulatory or legal issues disclosed in the latest filings, and the company appears to be operating within its financial and legal constraints.

With a debt-to-equity ratio of 0.07, Hayat Pharmaceutical carries substantially less leverage than the 0.18 cohort median.

Free cash flow grew 10.1% year-over-year to JOD 1.07 million, demonstrating improved cash generation capabilities.

The company faces low dilution, liquidity, and credit risks according to the provided risk flag assessments.

Revenue growth stagnated with a mere 0.8% four-year CAGR, reflecting limited top-line expansion potential.

Cash conversion sits in the bottom quartile of the cohort at -3.77, suggesting poor cash flow efficiency.